| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
HDAC1 0.17 μM (IC50) HDAC6 0.49 μM (IC50)
|
|---|---|
| ln Vitro |
HDAC-IN-73 (compound P-503) (0-10 µM; 48 h) inhibits the proliferation of HCT116 cells with an IC50 value of 0.24 µM, while the IC50 value of PsA is 3.05 µM[1]. Compared with PsA, HDAC-IN-73 (0.25-2 µM; 24 h) can increase the acetylation level of histone H3 or α-tubulin in HCT116 cells[1]. HDAC-IN-73 (0.1-0.2 µM; 24 h) can induce apoptosis of HCT116 cells and has a pro-apoptotic effect superior to that of PsA[1]. HDAC-IN-73 (0.2-0.4 µM; 48 h) can induce HCT116 cell cycle arrest at the G2/M phase, while PsA increases the proportion of the G1 phase[1]. Apoptosis Analysis[1] Cell Line: HCT116 cells Concentration: 0.2, 0.4 µM Incubation Time: 48 hours Result: Induced apoptosis with 71.94 % of apoptotic cells (both early and late apoptotic cells) at define concentration of 0.4 μM, compared with PsA (56.5 %, 4 μM) . Cell Cycle Analysis[1] Cell Line: HCT116 cells Con centration: 0.1, 0.2 µM Incubation Time: 24 hours Result: Induced cell cycle arrest at G2 / M phase while PsA increased proportion of G1 phase. HDAC-IN-73 with 0.1 μM and 0.2 μM can lead to 47.92 % and 74.56 % of the cells in G2 / M phase, respectively.
|
| ln Vivo |
HDAC-IN-73 (compound P-503) (5 mg/kg; ip; every 2 days for 26 days) had significant antitumor activity at 5 mg/kg in the HCT116 xenograft model, but also Higher toxicity, safety and toxic doses of HDAC-IN-73 require further study [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HCT116 Tested Concentrations: 0.25, 0.5, 1, 2 µM Incubation Duration: 24 hours Experimental Results: Increased the acetylation levels of histone H3 or α-tubulin in a dose dependent manner comparing with PsA. |
| Animal Protocol |
Animal/Disease Models:6 weeks, Female nude mice (BALB/c-nu) (HCT116 xenograft model)[1]
Doses: 5 mg/kg Route of Administration: I.p.; every 2 days for 26 days Experimental Results: Reduced the tumor volume (p < 0.0001) and the tumor weight (p < 0.01). Exhibited the significant loss of body weight which has the same trend with the group of negative control. Inhibited the tumor growth (TGI = 74.6 %) , while the TGI of SAHA (10 mg/kg, positive control) and PsA (10 mg/kg) were 13.1 % and 36.1 %, respectively. Existed high toxicity, 2 mice died during the medication. Western blot tests showed that the acetylation levels of histone H3 or α-tubulin in tumor tissues were up-regulated. |
| References |
| Molecular Formula |
C22H24BR2N4O6SE2
|
|---|---|
| Molecular Weight |
758.18
|
| Exact Mass |
759.837
|
| CAS # |
2323571-16-8
|
| PubChem CID |
142589371
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
6
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
36
|
| Complexity |
717
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=C(C=C1C/C(=N\\O)/C(=O)NCC[Se][Se]CCNC(=O)/C(=N/O)/CC2=CC(=C(C=C2)O)Br)Br)O
|
| InChi Key |
QSYYRWXQKANXFE-XUIWWLCJSA-N
|
| InChi Code |
InChI=1S/C22H24Br2N4O6Se2/c23-15-9-13(1-3-19(15)29)11-17(27-33)21(31)25-5-7-35-36-8-6-26-22(32)18(28-34)12-14-2-4-20(30)16(24)10-14/h1-4,9-10,29-30,33-34H,5-8,11-12H2,(H,25,31)(H,26,32)/b27-17+,28-18+
|
| Chemical Name |
(2E)-3-(3-bromo-4-hydroxyphenyl)-N-[2-[2-[[(2E)-3-(3-bromo-4-hydroxyphenyl)-2-hydroxyiminopropanoyl]amino]ethyldiselanyl]ethyl]-2-hydroxyiminopropanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3189 mL | 6.5947 mL | 13.1895 mL | |
| 5 mM | 0.2638 mL | 1.3189 mL | 2.6379 mL | |
| 10 mM | 0.1319 mL | 0.6595 mL | 1.3189 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
